Hematology Advisor Institute Spotlight Course

Medicine on the Move: Incorporating Novel JAK Inhibitors and Other Emerging Therapies into Higher-Risk Myelofibrosis Treatment

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.50 CME CE: Many patients with myelofibrosis are unresponsive or intolerant to ruxolitinib, learn about new JAK inhibitor therapies that provide options for these patients. Exp 2/24/24

Improving Outcomes in CAR T-cell Therapy for DLBCL | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: Patients with DLBCL face poor outcomes with salvage treatments. CAR T-cell therapy shows promise for patients with relapse after chemoimmunotherapy and ASCT. Exp 10/27/23

The Science Behind Anti-TFPI Therapy for Hemophilia | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

0.50 CME CE: Experts discuss the tissue factor pathway and its inhibitor, TFPI, in hemophilia, and the anticipated usefulness of anti-TFPI agents. Exp 6/29/24

Diagnosing and Treating Paroxysmal Nocturnal Hemoglobinuria | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s)

0.25 CME CE: Incorporating emerging paroxysmal nocturnal hemoglobinuria therapies and implementing a patient-centered approach to care. Exp 6/30/24

Changing Pharmacological Paradigms for Higher-Risk Myelofibrosis | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.00 CME CE: This course discusses how Individuals with intermediate and high-risk myelofibrosis stand to benefit the most from recently approved and investigational agents. Exp 5/19/24

Clinical Trial Equity in Non-Hodgkin Lymphoma | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Join a panel discussion on strategies to communicate with patients about the clinical-trial process for Non-Hodgkin Lymphoma. Exp 3/1/24

New Treatment of Paroxysmal Nocturnal Hemoglobinuria | myCME

AMA PRA Category 1 Credit(s)^TM

0.75 CME: Dr. Ilene Weitz takes a deep dive into recently published insights for treatment and management of this poorly understood hematologic disorder. Exp 6/15/24

Strategies to Address High-Risk Myelodysplastic Syndrome | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME: Experts discuss barriers to using new advances in care and to creating personalized treatment plans for patients with high-risk MDS. Exp 4/6/24

Mitigating Veno-occlusive Disease Risk in R/R ALL | myCME

AMA PRA Category 1 Credit(s)^TM

0.50 CME: Veno-occlusive disease is a life-threatening condition. Early recognition and management are paramount to recovery. This activity is designed for the interdisciplinary care team. Exp 12/2/23

Unmet Needs of Patients with Acute Hepatic Porphyria | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists, AAPA Category 1 CME Credit, ABIM MOC Points

1.50 CME CE: Two prominent experts in AHP help clinicians involved in hematology stay current with best practices for managing this disease. Exp 1/27/24

Advances in MDS Diagnosis and Individualized Treatment | myCME

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists

0.50 CME CE: Multimedia journey about the latest updates on the management of higher-risk MDS and the overlap between MDS and AML with mutated TP53. Exp 3/31/24

Maintenance Therapy for Acute Myeloid Leukemia | myCME

AMA PRA Category 1 Credit(s)^TM, CNE Contact Hour(s), CE for Pharmacists

1.00 CME CE: NCCN guidelines for patients with Acute Myeloid Leukemia that are eligible for maintenance and the importance of treatment goals. Exp 7/21/24

BCMA-Targeting Drugs in R/R Multiple Myeloma | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s), CE for Pharmacists

1.50 CME CE: Reviews data on how BCMA-targeting therapies help improve survival in patients with relapsed/refractory multiple myeloma. Exp 10/31/23